Valuation: Alvotech

Market Cap 1.83B 1.63B 1.51B 1.36B 2.57B 172B 2.6B 18.08B 7.09B 90.64B 6.86B 6.71B 289B P/E 2026 *
122x
P/E 2027 * 17.1x
Enterprise Value 2.9B 2.59B 2.39B 2.17B 4.08B 274B 4.13B 28.71B 11.27B 144B 10.89B 10.66B 459B EV / Sales 2026 *
4.45x
EV / Sales 2027 * 3.67x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+1.55%
1 week-3.22%
Current month-11.74%
1 month-9.07%
3 months+46.00%
6 months+47.47%
Current year+10.03%
1 week 49.35
Extreme 49.35
54.8
1 month 49.35
Extreme 49.35
64.9
Current year 27.5
Extreme 27.5
64.9
1 year 27.5
Extreme 27.5
81.75
3 years 27.5
Extreme 27.5
157
5 years 27.5
Extreme 27.5
157
10 years 27.5
Extreme 27.5
157
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 57 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-3.22% - - 1.83B
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+6.53%+11.68%+90.35% 52.92B
+0.82%+5.41%+8.05%+74.45% 54.82B
+3.04%+4.68%+25.43%+49.30% 44.09B
+0.52%+9.91%+22.35%+128.95% 43.72B
-0.98%+0.49%+263.54%+959.44% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+5.60%+36.60%+26.39% 23.37B
Average +0.36%+4.78%+52.35%+163.28% 43.06B
Weighted average by Cap. +0.26%+4.67%+51.42%+167.30%

Financials

2026 *2027 *
Net sales 653M 582M 538M 487M 918M 61.59B 929M 6.46B 2.53B 32.37B 2.45B 2.4B 103B 786M 700M 648M 587M 1.11B 74.16B 1.12B 7.77B 3.05B 38.98B 2.95B 2.89B 124B
Net income 2.25M 2M 1.85M 1.68M 3.16M 212M 3.2M 22.22M 8.72M 111M 8.43M 8.25M 355M 80.1M 71.38M 66.08M 59.8M 113M 7.56B 114M 792M 311M 3.97B 300M 294M 12.66B
Net Debt 1.08B 958M 887M 803M 1.51B 101B 1.53B 10.64B 4.17B 53.35B 4.03B 3.95B 170B 1.06B 941M 871M 788M 1.49B 99.64B 1.5B 10.44B 4.1B 52.38B 3.96B 3.88B 167B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
22/10/26 SEK 51.10 -0.97% 12,336
20/10/26 SEK 51.60 +2.99% 97,905
19/10/26 SEK 50.10 -0.20% 15,729
16/10/26 SEK 50.20 -3.83% 18,943
15/10/26 SEK 52.20 -1.14% 26,263
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.120USD
Average target price
7.200USD
Spread / Average Target
+40.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech